Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The manufacturing process for B-domain deleted recombinant factor VIII.

R K Eriksson1, C Fenge, E Lindner-Olsson

  • 1Pharmacia AB, Stockholm, Sweden.

Seminars in Hematology
|July 13, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New approach methodologies for evaluating developmental and reproductive toxicity potential: Review on state of the art, applicability for cosmetic related ingredients and coverage of developmental stages.

NAM journal·2026
Same author

Droplet Helical Motion on Twisted Fibers.

Langmuir : the ACS journal of surfaces and colloids·2024
Same author

An exploration of testicular cancer survivors' experience of ejaculatory dysfunction following retroperitoneal lymph node dissection-a sub-study of the PREPARE clinical trial.

Journal of cancer survivorship : research and practice·2023
Same author

Advancing the use of new approach methodologies for assessing teratogenicity: Building a tiered approach.

Reproductive toxicology (Elmsford, N.Y.)·2023
Same author

Optimal timing and technique for endoscopic management of dysphagia in pediatric aerodigestive patients.

International journal of pediatric otorhinolaryngology·2021
Same author

Pelvic and acetabular trauma in amateur equestrian enthusiasts - A retrospective review.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·2021

A new cell bank was developed for manufacturing B-domain deleted recombinant coagulation factor VIII (BDDrFVIII). This ensures a consistent, highly pure factor VIII product for hemophilia A treatment, free from human serum albumin.

Area of Science:

  • Biotechnology
  • Biopharmaceutical Manufacturing
  • Hematology

Background:

  • Hemophilia A treatment relies on factor VIII replacement therapy.
  • Current therapies may carry risks of viral or microbial contamination.
  • Development of safer, recombinant factor VIII is crucial.

Purpose of the Study:

  • To describe the development of a cell bank for B-domain deleted recombinant coagulation factor VIII (BDDrFVIII).
  • To outline the manufacturing process ensuring high purity and safety.
  • To confirm BDDrFVIII as a consistent therapeutic option.

Main Methods:

  • Stable insertion of the human BDDrFVIII gene into Chinese hamster ovary (CHO) cells.
  • Selection of high-expressing cell lines and cell bank establishment.

Related Experiment Videos

  • Multi-step purification including chromatography and viral inactivation.

    • Main Results:

    • Consistent expression of active BDDrFVIII achieved through cell line selection.
    • Purification process yielded a highly pure BDDrFVIII product.
    • Final formulation free of human serum albumin, enhancing safety.

    Conclusions:

    • The developed cell bank supports routine manufacturing of BDDrFVIII.
    • The manufacturing process ensures a safe and effective treatment for hemophilia A.
    • BDDrFVIII represents a reliable and pure factor VIII concentrate.